Literature DB >> 6502751

Gangliosides of human spinal cord: aberrant composition of cords from patients with amyotrophic lateral sclerosis.

G Dawson, K Stefansson.   

Abstract

The ganglioside content of formalin-fixed human spinal cords and fresh human spinal cords was found to be both quantitatively and qualitatively similar. However, the spinal cord was found to be heterogeneous with respect to ganglioside content. In particular, a gradient of GD1a was observed, increasing from a low content in the cervical region to a relatively high content in the sacral region. Comparison of the ganglioside content of nine normal spinal cords and nine spinal cords from clinically diagnosed amyotrophic lateral sclerosis (ALS) patients revealed no major quantitative differences, but the unique presence of three additional gangliosides in ALS spinal cords. One of these was tentatively identified as sialosylglobotetraosylceramide and was absent from eight of nine control spinal cord samples, the sole exception being the cord from a 97-year-old female.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6502751     DOI: 10.1002/jnr.490120209

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  10 in total

1.  Two species of antiganglioside antibodies in a patient with a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome.

Authors:  K Mizoguchi; A Hase; T Obi; H Matsuoka; M Takatsu; Y Nishimura; F Irie; Y Seyama; Y Hirabayashi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

2.  Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis.

Authors:  James C Dodge; Christopher M Treleaven; Joshua Pacheco; Samantha Cooper; Channa Bao; Marissa Abraham; Mandy Cromwell; S Pablo Sardi; Wei-Lien Chuang; Richard L Sidman; Seng H Cheng; Lamya S Shihabuddin
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-08       Impact factor: 11.205

3.  A characteristic ganglioside antibody pattern in the CSF of patients with amyotrophic lateral sclerosis.

Authors:  A Stevens; M Weller; H Wiethölter
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-04       Impact factor: 10.154

4.  Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomas.

Authors:  D C Longee; C J Wikstrand; J E Månsson; X He; G N Fuller; S H Bigner; P Fredman; L Svennerholm; D D Bigner
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

5.  Abnormal changes in NKT cells, the IGF-1 axis, and liver pathology in an animal model of ALS.

Authors:  Arseny Finkelstein; Gilad Kunis; Akop Seksenyan; Ayal Ronen; Tamara Berkutzki; David Azoulay; Maya Koronyo-Hamaoui; Michal Schwartz
Journal:  PLoS One       Date:  2011-08-02       Impact factor: 3.240

6.  Ganglioside deficiency causes inflammation and neurodegeneration via the activation of complement system in the spinal cord.

Authors:  Yuhsuke Ohmi; Yuki Ohkawa; Orie Tajima; Yasuo Sugiura; Keiko Furukawa; Koichi Furukawa
Journal:  J Neuroinflammation       Date:  2014-03-28       Impact factor: 8.322

7.  A(a)LS: Ammonia-induced amyotrophic lateral sclerosis.

Authors:  Bhavin Parekh
Journal:  F1000Res       Date:  2015-05-14

8.  Inhibition of β-Glucocerebrosidase Activity Preserves Motor Unit Integrity in a Mouse Model of Amyotrophic Lateral Sclerosis.

Authors:  Alexandre Henriques; Mylene Huebecker; Hélène Blasco; Céline Keime; Christian R Andres; Philippe Corcia; David A Priestman; Frances M Platt; Michael Spedding; Jean-Philippe Loeffler
Journal:  Sci Rep       Date:  2017-07-12       Impact factor: 4.379

Review 9.  Lipid Involvement in Neurodegenerative Diseases of the Motor System: Insights from Lysosomal Storage Diseases.

Authors:  James C Dodge
Journal:  Front Mol Neurosci       Date:  2017-11-03       Impact factor: 5.639

Review 10.  Exploring Sphingolipid Implications in Neurodegeneration.

Authors:  Alice V Alessenko; Elisabetta Albi
Journal:  Front Neurol       Date:  2020-05-21       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.